XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE K – SEGMENT REPORTING

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices. We measure and evaluate our reportable segments based on net sales of reportable segments, operating income of reportable segments, excluding intersegment profits, and operating income of reportable segments as a percentage of net sales of reportable segments. Operating income of reportable segments as a percentage of net sales of reportable segments is defined as operating income of reportable segments divided by net sales of reportable segments. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition/divestitures-related net charges/(credits), restructuring and restructuring-related net charges/(credits), certain EU Medical Device Regulation (MDR) implementation costs and litigation-related charges/(credits). Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes in our unaudited condensed consolidated statements of operations and are included in the reconciliation below.

Following our integration of BTG, the acquisition of which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. In our Quarterly Report on Form 10-Q for the period ended September 30, 2019, we presented Interventional Medicine and Specialty Pharmaceuticals together as "BTG Acquisition" and outside of our operating and reportable segments for sales of reportable segments, operating income of reportable segments, excluding intersegment profits, and operating income of reportable segments as a percentage of net sales of reportable segments. We have revised amounts for the third quarter and first nine months of 2019 to conform to the current year presentation.
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
Three Months Ended
September 30,		Nine Months Ended
September 30,
Net sales2020201920202019
MedSurg$825 $845$2,175 $2,429
Rhythm and Neuro757 7801,985 2,323
Cardiovascular1,002 1,0582,862 3,057
Total net sales of reportable segments2,584 2,6847,021 7,807
All other (Specialty Pharmaceuticals)74 23183 23
Consolidated net sales$2,659 $2,707$7,204 $7,831
Three Months Ended
September 30,		Nine Months Ended
September 30,
Income (loss) before income taxes2020201920202019
MedSurg$307 $319$738 $870
Rhythm and Neuro165 166296 488
Cardiovascular208 283593 860
Total operating income of reportable segments680 7681,628 2,218
All other (Specialty Pharmaceuticals)49 13124 13
Unallocated amounts:
Corporate expenses, including hedging activities(108)(75)(330)(215)
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits(629)(146)(957)(210)
Amortization expense(197)(178)(595)(498)
Operating income (loss)(205)383(130)1,308
Other expense, net(22)(292)(256)(615)
Income (loss) before income taxes$(227)$91$(386)$693
Operating income of reportable segments as a percentage of net sales of reportable segmentsThree Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
MedSurg37.2 %37.8 %33.9 %35.8 %
Rhythm and Neuro21.9 %21.3 %14.9 %21.0 %
Cardiovascular20.8 %26.7 %20.7 %28.1 %